Literature DB >> 30786794

Preeclampsia outcomes at delivery and race.

Cynthia Gyamfi-Bannerman1, Ambika Pandita2, Eliza C Miller3, Amelia K Boehme2,3, Jason D Wright1, Zainab Siddiq1, Mary E D'Alton1, Alexander M Friedman1.   

Abstract

Objective: The objective of this study was to assess how race is associated with adverse maternal outcomes in the setting of preeclampsia.Study design: This retrospective cohort study utilized the National (Nationwide) Inpatient Sample (NIS) from the Agency for Health care Research and Quality for the years 2012-2014. Women aged 15-54 with a diagnosis of preeclampsia were included. Race and ethnicity were categorized as non-Hispanic white, non-Hispanic black, Hispanic, Asian or Pacific Islander, Native American, other, and unknown. The overall risk for severe morbidity based on Centers for Disease Control and Prevention criteria was analyzed along with the risk for specific outcomes such as stroke, acute heart failure or pulmonary edema, eclampsia, and acute renal failure. The risk for severe morbidity was stratified by comorbid risk and compared by race. Log-linear regression models were created to assess risk for severe morbidity with risk ratios and associated 95% confidence intervals as measures of effect.
Results: A total of 101,741 women with preeclampsia from 2012 to 2014 were included in this analysis. The risk for severe morbidity was significantly higher among non-Hispanic black women (9.8%) than non-Hispanic white, Hispanic, and all other women, respectively (6.1, 7.7, and 7.5%, respectively, p < .01). For non-Hispanic black compared to non-Hispanic white, Hispanic, and all other women, risk was higher for stroke (17.1 versus 6.5, 12.7, and 9.3 per 10,000 deliveries, respectively, p < .01) and pulmonary edema or heart failure (56.2 versus 32.7, 30.2, and 38.4 per 10,000 deliveries, respectively, p < .01). Non-Hispanic black women were also more likely than non-Hispanic white women to experience renal failure (136.4 versus 60.4 per 10,000 deliveries, p < .01). Adjusting for comorbidity, black women remained at higher risk for severe morbidity (p < .01). The risk for death was higher for black compared to non-black women (121.8 per 100,000 deliveries, 95% CI 69.7-212.9 versus 24.1 per 100,000 deliveries, 95% CI 14.6-39.8, respectively, p < .01)
Conclusion: Black women were at higher risk for severe morbidity and mortality associated with preeclampsia.

Entities:  

Keywords:  Maternal risk; preeclampsia; racial disparities

Mesh:

Year:  2019        PMID: 30786794      PMCID: PMC6790144          DOI: 10.1080/14767058.2019.1581522

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  21 in total

1.  An enhanced method for identifying obstetric deliveries: implications for estimating maternal morbidity.

Authors:  Elena V Kuklina; Maura K Whiteman; Susan D Hillis; Denise J Jamieson; Susan F Meikle; Samuel F Posner; Polly A Marchbanks
Journal:  Matern Child Health J       Date:  2007-08-10

Review 2.  Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data.

Authors:  Vincenzo Berghella; Anthony O Odibo; Meekai S To; Orion A Rust; Sietske M Althuisius
Journal:  Obstet Gynecol       Date:  2005-07       Impact factor: 7.661

3.  Pregnancy-Related Mortality in the United States, 2011-2013.

Authors:  Andreea A Creanga; Carla Syverson; Kristi Seed; William M Callaghan
Journal:  Obstet Gynecol       Date:  2017-08       Impact factor: 7.661

4.  Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial.

Authors:  B M Sibai; B M Mercer; E Schiff; S A Friedman
Journal:  Am J Obstet Gynecol       Date:  1994-09       Impact factor: 8.661

5.  Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery.

Authors:  Steven L Clark; Michael A Belfort; Gary A Dildy; Melissa A Herbst; Janet A Meyers; Gary D Hankins
Journal:  Am J Obstet Gynecol       Date:  2008-05-02       Impact factor: 8.661

Review 6.  Magnesium sulfate therapy in preeclampsia and eclampsia.

Authors:  A G Witlin; B M Sibai
Journal:  Obstet Gynecol       Date:  1998-11       Impact factor: 7.661

7.  Black-white differences in severe maternal morbidity and site of care.

Authors:  Elizabeth A Howell; Natalia Egorova; Amy Balbierz; Jennifer Zeitlin; Paul L Hebert
Journal:  Am J Obstet Gynecol       Date:  2015-08-15       Impact factor: 8.661

8.  Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications.

Authors:  Baha M Sibai; John R Barton
Journal:  Am J Obstet Gynecol       Date:  2007-06       Impact factor: 8.661

9.  Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis.

Authors:  Cande V Ananth; Katherine M Keyes; Ronald J Wapner
Journal:  BMJ       Date:  2013-11-07

10.  Validation of an obstetric comorbidity index in an external population.

Authors:  A Metcalfe; L M Lix; J-A Johnson; G Currie; A W Lyon; F Bernier; S C Tough
Journal:  BJOG       Date:  2015-01-05       Impact factor: 6.531

View more
  13 in total

1.  Infection During Delivery Hospitalization and Risk of Readmission for Postpartum Stroke.

Authors:  Eliza C Miller; Timothy Wen; Mitchell S V Elkind; Alexander M Friedman; Amelia K Boehme
Journal:  Stroke       Date:  2019-08-15       Impact factor: 7.914

Review 2.  The Impact of Sex and Gender on Stroke.

Authors:  Kathryn M Rexrode; Tracy E Madsen; Amy Y X Yu; Cheryl Carcel; Judith H Lichtman; Eliza C Miller
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

Review 3.  Health Disparities Across the Continuum of ASCVD Risk.

Authors:  Ankita Devareddy; Ashish Sarraju; Fatima Rodriguez
Journal:  Curr Cardiol Rep       Date:  2022-07-05       Impact factor: 3.955

Review 4.  Hypertensive Disorders of Pregnancy and Cardiovascular Disease Risk Across Races and Ethnicities: A Review.

Authors:  Renée J Burger; Hannelore Delagrange; Irene G M van Valkengoed; Christianne J M de Groot; Bert-Jan H van den Born; Sanne J Gordijn; Wessel Ganzevoort
Journal:  Front Cardiovasc Med       Date:  2022-06-28

5.  Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association.

Authors:  Vesna D Garovic; Ralf Dechend; Thomas Easterling; S Ananth Karumanchi; Suzanne McMurtry Baird; Laura A Magee; Sarosh Rana; Jane V Vermunt; Phyllis August
Journal:  Hypertension       Date:  2021-12-15       Impact factor: 9.897

6.  Fetal sex and risk of preeclampsia: Dose maternal race matter?

Authors:  Hooman Mirzakhani; Scott T Weiss
Journal:  J Matern Fetal Neonatal Med       Date:  2020-09-13

Review 7.  A Critical Review on the Use of Race in Understanding Racial Disparities in Preeclampsia.

Authors:  Henrietta O Fasanya; Chu J Hsiao; Kendra R Armstrong-Sylvester; Stacy G Beal
Journal:  J Appl Lab Med       Date:  2021-01-12

8.  Racial Disparities in Cardiovascular Complications With Pregnancy-Induced Hypertension in the United States.

Authors:  Anum S Minhas; S Michelle Ogunwole; Arthur Jason Vaught; Pensee Wu; Mamas A Mamas; Martha Gulati; Di Zhao; Allison G Hays; Erin D Michos
Journal:  Hypertension       Date:  2021-06-08       Impact factor: 9.897

9.  Beat-to-Beat Blood Pressure Variability in the First Trimester Is Associated With the Development of Preeclampsia in a Prospective Cohort: Relation With Aortic Stiffness.

Authors:  Virginia R Nuckols; Seth W Holwerda; Rachel E Luehrs; Lyndsey E DuBose; Amy K Stroud; Debra Brandt; Alexandria M Betz; Jess G Fiedorowicz; Sabrina M Scroggins; Donna A Santillan; Justin L Grobe; Curt D Sigmund; Mark K Santillan; Gary L Pierce
Journal:  Hypertension       Date:  2020-09-21       Impact factor: 9.897

10.  Racial Discrimination and Stress Across the Life Course: Associations With Prenatal Inflammation, Perceived Stress, and Depressive Symptoms.

Authors:  Shannon L Gillespie; Seuli Bose-Brill; Carmen Giurgescu; Kaboni W Gondwe; Timiya S Nolan; Elizabeth J Spurlock; Lisa M Christian
Journal:  Nurs Res       Date:  2021 Set/Oct 01       Impact factor: 2.381

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.